GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.

ABSTRACT:

Rationale

GlycA, an emerging inflammatory biomarker, predicted cardiovascular events in population-based studies. Psoriasis, an inflammatory disease associated with increased cardiovascular risk, provides a model to study inflammatory biomarkers in cardiovascular disease (CVD). Whether GlycA associates with psoriasis and how it predicts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown.

Objective

To investigate the relationships between GlycA and psoriasis and between GlycA and subclinical CVD.

Methods and results

Patients with psoriasis and controls (n=412) participated in a 2-stage study. We measured GlycA by nuclear magnetic resonance spectroscopy. National Institutes of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Po

SUBMITTER: Joshi AA 

PROVIDER: S-EPMC5215065 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature